Navigation Links
Vidaza Significantly Extends Overall Survival by 74% in Phase 3 Trial in Myelodysplastic Syndromes (MDS)
Date:8/19/2007

Pharmion

Pharmion is a biopharmaceutical company focused on acquiring, developing and commercializing innovative products for the treatment of hematology and oncology patients in the U.S., Europe and additional international markets. Pharmion has a number of products on the market including the world's first approved epigenetic drug, Vidaza(R), a DNA demethylating agent. For additional information about Pharmion, please visit the company's website at http://www.pharmion.com.

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: This press release contains forward-looking statements, including summary statements relating to top line results of the Vidaza Survival Study and summary statements relating to the potential efficacy of Vidaza based on those results. Such statements are based on current expectations and beliefs only and are subject to risks and uncertainties, many of which are beyond our control, that could cause the final results to differ significantly from the results summarized by such statements. Actual results could differ materially depending on a number of factors, and we caution investors not to place undue reliance on the forward-looking statements contained in this press release. In particular, there can be no guarantee that topline results from the clinical trial discussed in this press release will be confirmed upon full analysis of the results of the Vidaza Survival Study and additional information relating to the safety, efficacy or tolerability of Vidaza may be discovered upon further analysis of data from the Vidaza Survival Study or analysis of additional data from other ongoing Vidaza clinical trials. Furthermore, even if these topline results are confirmed upon full analysis of the study, we cannot guarantee that Vidaza will be approved for marketing in a timely manner, if at all, by regulatory authorities in the EU or that information from the stu
'/>"/>

SOURCE Pharmion Corporation

Copyright©2007 PR Newswire.

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Clinical Data Reported on Vidaza in Hematologic Malignancies and Advanced Solid Tumors
2. Liraglutide provides significantly better glucose control than insulin glargine in phase 3 study
3. Arterial Plaque Significantly Reduced in Women Age 50-59 Taking Hormones, Says New Analysis of Womens Health Initiative Data
4. Prexige Study Shows Significantly Less Impact on Blood Pressure Than Ibuprofen in Osteoarthritis Patients with Controlled Hypertension
5. Lumiracoxib Study Showed Significantly Less Impact on Blood Pressure Than Ibuprofen in Osteoarthritis Patients with Controlled Hypertension
6. Actemra (tocilizumab) Significantly Improves Symptoms of Rheumatoid Arthritis Compared to a Current Standard of Care
7. Next Safety, Inc.s Innovative Drug Delivery System Will Replace Cigarettes and Significantly Advance Pulmonary Medication Delivery
8. Ivivis PEMF Technology Significantly Improves Neuron Survival in Parkinsons Disease Model, Study Finds
9. Mercks Investigational Migraine Treatment MK-0974 Significantly Improved Migraine Pain on Several Efficacy Measures in a Phase II Study
10. The Eloxatin-Based Regimen (FOLFOX4) Significantly Improved Progression Free Survival When Given Before and After Surgery in Patients With Resectable Liver Metastases From Colorectal Cancer
11. Nexavar Significantly Extends Overall Survival by 44% in Liver Cancer Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2015)... CHICAGO , Aug. 27, 2015  Hill-Rom Holdings, ... to a management presentation at the Morgan Stanley Global ... ET. You are invited to listen to ... http://ir.hill-rom.com/events.cfm  or access it directly at https://cc.talkpoint.com/morg007/091615a_ae/?entity=49_UCJPU8N . ... be available one hour after the conclusion of the ...
(Date:8/27/2015)... pharmaceutical and medical device companies and leading law firms will ... on Oct. 20, discussing issues surrounding regulatory compliance, ... Litigation Conferences has announced. To learn more ... The program is co-chaired by Megan Grossman ... Hart Yeary of Dechert LLP. Topics include: ...
(Date:8/27/2015)... , August 27, 2015 ... announced a private investment in public equity (PIPE) deal, ... $28.4 million in Itamar Medical.   Through ... shareholder of Itamar Medical and will work closely with ... According to the investment agreement, Itamar Medical ...
Breaking Medicine Technology:Pharmaceutical, Medical Device Law Seminar Features In-House, Outside Counsel 2Pharmaceutical, Medical Device Law Seminar Features In-House, Outside Counsel 3Viola Private Equity Invests up to $28.4 Million in Itamar Medical and Becomes the Largest Shareholder of the Company 2Viola Private Equity Invests up to $28.4 Million in Itamar Medical and Becomes the Largest Shareholder of the Company 3Viola Private Equity Invests up to $28.4 Million in Itamar Medical and Becomes the Largest Shareholder of the Company 4Viola Private Equity Invests up to $28.4 Million in Itamar Medical and Becomes the Largest Shareholder of the Company 5
... 20, 2011 Comprehensive Care Corporation (OTC BB: CHCR), ... management services for managed care companies throughout the U.S., ... has been praised by the Chamber of Commerce of ... Leadership Advisory Council in "helping to shape and drive ...
... YDNT ) today announced record earnings per share for ... ended September 30, 2011. Sales for the third quarter ... $26.4 million reported for the third quarter of 2010. Income from ... $6.1 million in the prior year quarter. Net income for the ...
Cached Medicine Technology:Comprehensive Care Corporation CEO Clark A. Marcus Praised for U.S. Chamber of Commerce Service 2Young Innovations, Inc. Announces Record EPS for the Quarter and Record Sales and EPS for the Nine-Months Ended September 30, 2011 and Declares Quarterly Dividend 2Young Innovations, Inc. Announces Record EPS for the Quarter and Record Sales and EPS for the Nine-Months Ended September 30, 2011 and Declares Quarterly Dividend 3Young Innovations, Inc. Announces Record EPS for the Quarter and Record Sales and EPS for the Nine-Months Ended September 30, 2011 and Declares Quarterly Dividend 4Young Innovations, Inc. Announces Record EPS for the Quarter and Record Sales and EPS for the Nine-Months Ended September 30, 2011 and Declares Quarterly Dividend 5
(Date:8/27/2015)... Yardley, Penn. (PRWEB) , ... August 27, 2015 ... ... engagement solutions, confirmed today that its Krames Patient Education content is ICD-10 ready ... and is ready for the new ICD-10 code sets, which are more targeted ...
(Date:8/27/2015)... ... August 27, 2015 , ... More destinations and stores are becoming pet-friendly, ... Amica Insurance is sharing some tips to help your whole family travel safely and ... travel with pets each year. Amica is sharing the following tips from the American ...
(Date:8/27/2015)... and OKLAHOMA CITY, OK (PRWEB) , ... August ... ... Point Partners (“GPP”) I, LP portfolio company and leading biopharmaceutical contract development manufacturing ... be acquired by Hepalink USA Inc. (“Hepalink”) for $205.68M in cash. ...
(Date:8/27/2015)... ... 27, 2015 , ... Florida Hospital North Pinellas, located at 1395 South Pinellas Avenue in Tarpon ... The new facility will be located at US Highway 19 North and Highlands Boulevard, less ... 18, and work on the project is slated to begin in September 2015. ...
(Date:8/27/2015)... Collegedale, Tennessee (PRWEB) , ... August 27, 2015 , ... ... preservatives or high fructose corn syrup, is changing the expectation of how protein bars ... a rich, indulgent taste unlike any other protein bar on the market today. ...
Breaking Medicine News(10 mins):Health News:StayWell announces all health content is ICD-10 ready 2Health News:StayWell announces all health content is ICD-10 ready 3Health News:Amica Unleashes 5 Tips for Safe Traveling with Pets 2Health News:Great Point Partners, LLC Announces that Hepalink USA Inc. Agrees to Acquire Cytovance Biologics, Inc. 2Health News:Great Point Partners, LLC Announces that Hepalink USA Inc. Agrees to Acquire Cytovance Biologics, Inc. 3Health News:Great Point Partners, LLC Announces that Hepalink USA Inc. Agrees to Acquire Cytovance Biologics, Inc. 4Health News:Florida Hospital North Pinellas is Opening a New Free-Standing Emergency Room in Palm Harbor 2Health News:Florida Hospital North Pinellas is Opening a New Free-Standing Emergency Room in Palm Harbor 3Health News:Sunbelt® Bakery Changes the Expectations of How Protein Bars Should Taste with the Introduction of Its New Protein Delights 2Health News:Sunbelt® Bakery Changes the Expectations of How Protein Bars Should Taste with the Introduction of Its New Protein Delights 3
... from having problems paying medical bills, and having bill problems ... medicines, a new study has found. According to a ... Journal of Public Health , after taking age, income and ... the odds of accruing debt related to medical care or ...
... Alan Mozes HealthDay Reporter , THURSDAY, June 16 ... habits of America,s teens, new data from the U.S. Centers ... Not only are high school kids guzzling far too ... CDC research team found. In fact, just one in ...
... pilot study of etanercept for treatment of dermatomyositis found ... the drug were successfully weaned from steroid therapy. These ... further investigate the safety and efficacy of etanercept. Results ... of Neurology , a journal published by Wiley-Blackwell on ...
... new study published today in the journal Child ... a poor "gut sense" of numbers can lead to ... math proficiency. This inaccurate number sense is just one ... led by Dr. Michele Mazzocco of the Kennedy Krieger ...
... UT Southwestern Medical Center scientists are shedding new ... fast-acting antidepressant response in patients with treatment-resistant depression. ... as a fast-acting antidepressant potentially has use in emergency ... very sharp increase that immediately relieves depression," said Dr. ...
... of death across a population has evolved in recent ... heart attack and cancer, the role of behavioral factorsincluding ... the 1990s. More recent research has begun to ... mortality. In the first comprehensive analysis of such studies, ...
Cached Medicine News:Health News:Medical debt occurs despite insurance, UA study shows 2Health News:High School Kids Get Too Many Sugary Drinks, Too Little Exercise: CDC 2Health News:High School Kids Get Too Many Sugary Drinks, Too Little Exercise: CDC 3Health News:Etanercept shows promise for treating dermatomyositis 2Health News:Poor 'gut sense' of numbers contributes to persistent math difficulties 2Health News:Poor 'gut sense' of numbers contributes to persistent math difficulties 3Health News:How many US deaths are caused by poverty, low levels of education and other social factors? 2
The VascoTip J 9/60 PU is a unipolar tined, J-preformed permanent pacing lead. Due to advanced technology, VascoTip J 9/60 PU M is compatible to all pacemaker-cavities with the size of IS-1 (3.2 mm),...
VascoTip is a unipolar tined permanent pacing lead. Due to advanced technology, VascoTip 9/60 M is compatible to all pacemaker-cavities with the size of IS-1 (3.2 mm), 5 mm, 6 mm....
VascoTip is a unipolar tined permanent pacing lead. Due to advanced technology, VascoTip 9/60 M is compatible to all pacemaker-cavities with the size of IS-1 (3.2 mm), 5 mm, 6 mm....
VascoTip is a unipolar tined permanent pacing lead. Due to advanced technology, VascoTip 9/60 M is compatible to all pacemaker-cavities with the size of IS-1 (3.2 mm), 5 mm, 6 mm....
Medicine Products: